Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.
Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable drugs in the gastric environment. This approach allows the drug to pass safely through the stomach to regions of the GI tract where it can be more effectively absorbed.
Complexing agents like β-cyclodextrins are utilized to enhance drug stability by forming inclusion complexes. These agents can significantly increase the solubility and stability of poorly soluble drugs, thereby improving their bioavailability.
Bioadhesive delivery systems and controlled-release microencapsulated systems represent advanced strategies for prolonging the drug's presence in the GI tract. These systems adhere to the mucosal surfaces, allowing for a more sustained drug release. Co-administering drugs with metabolism inhibitors is another strategy to enhance bioavailability. This method involves using substances that inhibit the drug's metabolism within the GI tract or liver, preventing premature degradation.
Gastro-retentive drug delivery systems are designed to localize the delivery device in the stomach or small intestine, enhancing GI tract retention. By doing so, these systems ensure that the drug remains in the absorption site for longer, improving its bioavailability.
Bioadhesive or swelling excipients, such as cellulose ethers or natural gums, are employed to increase the drug's contact time with epithelial surfaces. These materials can swell upon contact with gastric fluids, increasing their size and making them more retentive within the stomach. This prolongs the stomach residence time and delays the drug's intestinal transit, allowing for improved absorption and effectiveness.
These diverse methods collectively aim to optimize drug stability and bioavailability within the GI tract, ensuring that patients receive the maximum therapeutic benefits from their medications.
A drug’s stability in the GI tract can be improved through various methods.
Polymer coating prevents drug release in the stomach, improving drug absorption in the gastric milieu.
The stability can also be enhanced by using complexing agents like β-cyclodextrins.
Some approaches, like bioadhesive delivery systems and controlled-release microencapsulated systems, co-administer the drug with metabolism inhibitors to enhance bioavailability.
For example, the co-administration of erythromycin can significantly enhance the bioavailability of cyclosporin.
Gastro-retentive drug delivery systems localize the delivery device in the stomach, improving GI tract retention.
Bioadhesive or swelling excipients like cellulose ethers or natural gums increase contact with epithelial surfaces, prolonging stomach residence time and delaying intestinal transit.
繁體中文
